Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 301 AL 315

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

de Matos AM, de Macedo MP, Rauter AP.

Med Res Rev. 2018 Jan;38(1):261-324. doi: 10.1002/med.21440. Epub 2017 Apr 19.

Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease

Zhao N, Liu CC, Qiao W, Bu G.

Biol Psychiatry. 2018 Feb 15;83(4):347-357. doi: 10.1016/j.biopsych.2017.03.003. Epub 2017 Mar 14.

Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches

Corrêa-Velloso JC, Gonçalves MC, Naaldijk Y, Oliveira-Giacomelli Á, Pillat MM, Ulrich H.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt A):34-53. doi: 10.1016/j.pnpbp.2017.04.033. Epub 2017 May 3.

[Anti-ageing therapies in Alzheimer's disease]

Alonso Abreu GS, Brito Armas JM, Castro Fuentes R.

Rev Esp Geriatr Gerontol. 2018 Jan-Feb;53(1):45-53. doi: 10.1016/j.regg.2017.02.007. Epub 2017 May 24.

Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission

Korábečný J, Nepovimová E, Cikánková T, Špilovská K, Vašková L, Mezeiová E, Kuča K, Hroudová J.

Neuroscience. 2018 Feb 1;370:191-206. doi: 10.1016/j.neuroscience.2017.06.034. Epub 2017 Jul 1.

Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease

Taylor JM, Moore Z, Minter MR, Crack PJ.

J Neural Transm (Vienna). 2018 May;125(5):797-807. doi: 10.1007/s00702-017-1745-4. Epub 2017 Jul 4.

Mechanistic comparison of current pharmacological treatments and novel phytochemicals to target amyloid peptides in Alzheimer's and neurodegenerative diseases

Ayyalasomayajula N, Suresh C.

Nutr Neurosci. 2018 Dec;21(10):682-694. doi: 10.1080/1028415X.2017.1345425. Epub 2017 Jul 6.

Targeting Fyn Kinase in Alzheimer's Disease

Nygaard HB.

Biol Psychiatry. 2018 Feb 15;83(4):369-376. doi: 10.1016/j.biopsych.2017.06.004. Epub 2017 Jun 13.

BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease

Prati F, Bottegoni G, Bolognesi ML, Cavalli A.

J Med Chem. 2018 Feb 8;61(3):619-637. doi: 10.1021/acs.jmedchem.7b00393. Epub 2017 Aug 8.

Targeting NAD(+) degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty

Ruan Q, Ruan J, Zhang W, Qian F, Yu Z.

Pharmacol Res. 2018 Feb;128:345-358. doi: 10.1016/j.phrs.2017.08.010. Epub 2017 Aug 25.

Modulation of γ- and β-Secretases as Early Prevention Against Alzheimer's Disease

Voytyuk I, De Strooper B, Chávez-Gutiérrez L.

Biol Psychiatry. 2018 Feb 15;83(4):320-327. doi: 10.1016/j.biopsych.2017.08.001. Epub 2017 Aug 10.

Therapeutic peptides for CNS indications: Progress and challenges

Morimoto BH.

Bioorg Med Chem. 2018 Jun 1;26(10):2859-2862. doi: 10.1016/j.bmc.2017.09.011. Epub 2017 Sep 9.

Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease

Kaushik V, Smith ST, Mikobi E, Raji MA.

Am J Alzheimers Dis Other Demen. 2018 Mar;33(2):73-85. doi: 10.1177/1533317517734352. Epub 2017 Oct 3.

Curcumin or bisdemethoxycurcumin for nose-to-brain treatment of Alzheimer disease? A bio/chemo-informatics case study

Hathout RM, El-Ahmady SH, Metwally AA.

Nat Prod Res. 2018 Dec;32(24):2873-2881. doi: 10.1080/14786419.2017.1385017. Epub 2017 Oct 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias